{"commentary":{"count":11,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":6,"x_thread":3,"youtube":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03428217\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CANTATA","nct_id":"NCT03428217","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cantata-nct03428217. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"CANTATA","arms":[{"description":"Placebo twice daily (BID) + cabozantinib (60 mg once daily \\[QD\\]) administered orally on Days 1 through 28 of each 28-day cycle until disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or unacceptable toxicity, whichever occurred first.","label":"Pbo-Cabo","type":"PLACEBO_COMPARATOR"},{"description":"CB-839 800 mg BID + cabozantinib (60 mg QD) administered orally on Days 1 through 28 of each 28-day cycle until disease progression per RECIST v1.1 or unacceptable toxicity, whichever occurred first.","label":"CB-Cabo","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2021-07-16","type":"ACTUAL"},"conditions":["Advanced Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma"],"enrollment":{"count":444,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"CB-839","type":"DRUG"},{"name":"Cabozantinib","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2023-03-20","lead_sponsor":"Calithera Biosciences, Inc","official_title":"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2020-08-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC)","timeFrame":"Up to the primary analysis data cut-off date of 31 Aug 2020. Maximum duration of follow-up for PFS was 22.14 months."}],"references":[{"citation":"Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O Jr, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Mellado B, Sepulveda Sanchez JM, Figlin R, Powles T, Akella L, Orford K, Escudier B. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1411-1418. doi: 10.1001/jamaoncol.2022.3511.","pmid":"36048457","type":"DERIVED"}],"start_date":{"date":"2018-04-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT03428217"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cantata-nct03428217"}